Biomedical subjects

G Gastl

Publications and source records attributed to G Gastl.

111 records · Page 7Linked to original sources

PubMed1982

[Density distribution of human lymphocytes. I. Results of research on normal lymphoid tissue].

The aim of this study was to analyze the density distribution patterns of subsets of normal human lymphocytes. Density distribution was assessed by equilibrium centrifugation on linear polysucrose-metrizoat gradients. Results of the analyses of various subsets of lymphoid cells differing in their degree of cellular maturation and functional activation suggested that their distribution patterns are determined by three independent factors: the derivation, the stage of differenciation and the functional activity.

B-Lymphocytes↗

PubMed1981

[Influence of sport on the cardiovascular system in pregnancy (author's transl)].

Stroke volume and cardiac output were determined in 24 pregnant women at the end of the first and second trimenon. There was a decrease of cardiac output in 7 women (29%) and among these a decrease of stroke volume in 6 women (25%). In this group there were especially untrained women with a high incidence of "health complications" during pregnancy.

Adult↗

PubMedDate not supplied

Angiogenesis as a target for tumor treatment.

Angiogenesis is a key step in tumor growth, invasion and metastasis. Thus, antiangiogenic therapy was postulated to be an attractive approach for antitumor treatment. Based on today's knowledge, at least three strategies for inhibition of angiogenesis are feasible: (1) inhibition of release of angiogenic factors from tumor cells and/or neutralization of angiogenic molecules that have already been released: (2) inhibition of vascular endothelial cell proliferation and migration, and (3) inhibition of the synthesis and turnover of vessel basement membrane. To date, a number of antiangiogenic agents have been identified. In animal models, treatment with angiogenesis inhibitors has proven antitumor effects. Early clinical experience with angiogenic inhibitors indicates that optimal antiangiogenic therapy in the future is likely to be based on the long-term administration to cancer patients in adjunct to surgery, radiotherapy and conventional chemotherapy.

Animals↗